Skip to Content

Fulvicin P / G (griseofulvin) Disease Interactions

There are 3 disease interactions with Fulvicin P / G (griseofulvin):

Major

Griseofulvin (Includes Fulvicin P/G) ↔ hepatic dysfunction

Severe Potential Hazard, Moderate plausibility. Applies to: Liver Disease

The use of griseofulvin is contraindicated in patients with hepatocellular failure, as animal data has shown that this drug may cause hepatocellular necrosis. The use of griseofulvin has not been adequately studied in patients with liver disease, although it is known that griseofulvin is primarily metabolized by the liver. Therapy with griseofulvin should be administered very cautiously in patients with liver impairment, and the dosing adjusted or discontinued according to clinical response.

References

  1. "Product Information. Fulvicin P/G (griseofulvin)." Schering Laboratories, Kenilworth, NJ.
Major

Griseofulvin (Includes Fulvicin P/G) ↔ porphyria

Severe Potential Hazard, High plausibility. Applies to: Porphyria

The use of griseofulvin is contraindicated in patients with porphyria. Griseofulvin has been shown to cause disturbances in porphyrin metabolism in laboratory animals.

References

  1. "Product Information. Fulvicin P/G (griseofulvin)." Schering Laboratories, Kenilworth, NJ.
Moderate

Griseofulvin (Includes Fulvicin P/G) ↔ lupus erythematosus

Moderate Potential Hazard, Moderate plausibility. Applies to: Lupus Erythematosus

The use of griseofulvin has been associated with the development of lupus erythematosus and lupus-like syndromes, as well as exacerbation of the disease. Griseofulvin therapy should be withdrawn in patients experiencing worsening of preexisting lupus until another cause can be identified.

References

  1. Miyagawa S, Sakamoto K "Adverse reaction to griseofulvin in patients with circulating anti-ssa/ro and ssb/la autoantibodies." Am J Med 87 (1989): 99-102
  2. Miyagawa S, Okuchi T, Shiomi Y, Sakamoto K "Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin." J Am Acad Dermatol 21 (1989): 343-6
  3. Madhok R, Zoma A, Capell H "Fatal exacerbation of systemic lupus erythematosus after treatment with griseofulvin." Br Med J (Clin Res Ed) 291 (1985): 249-50
  4. "Product Information. Fulvicin P/G (griseofulvin)." Schering Laboratories, Kenilworth, NJ.
View all 4 references

Fulvicin P / G (griseofulvin) drug interactions

There are 360 drug interactions with Fulvicin P / G (griseofulvin)

Fulvicin P / G (griseofulvin) alcohol/food interactions

There is 1 alcohol/food interaction with Fulvicin P / G (griseofulvin)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide